Skip to main content

Table 3 Share (%) of reimbursed ultra-orphan, oncology orphan and other orphan drugs by type of HTA recommendation, by country

From: The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe

  All orphan (101) Ultra-orphan Oncology orphan Non-ultra, non-oncology orphan drugs
Positive Conditional Negative Not assessed Positive Conditional Negative Not assessed Positive Conditional Negative Not assessed Positive Conditional Negative Not assessed
England 25 % 0 % 14 % 11 % 0 % 0 % 0 % 24 % 33 % 0 % 0 % 0 % 20 % 0 % 50 % 12 %
Germany 76 % 0 % 0 % 1 % 100 % 0 % 0 % 0 % 73 % 0 % 0 % 0 % 77 % 0 % 0 % 3 %
Poland 71 % 69 % 31 % 6 % 100 % 100 % 50 % 27 % 100 % 67 % 38 % 0 % 33 % 57 % 17 % 3 %
Netherlands 20 % 75 % 40 % 10 % 0 % 75 % 100 % 8 % 0 % 83 % 33 % 17 % 33 % 72 % 0 % 7 %
Sweden 100 % 0 % 0 % 0 % 100 % 0 % 0 % 0 % 100 % 0 % 0 % 0 % 100 % 0 % 0 % 0 %
Scotland 19 % 0 % 10 % 5 % 40 % 0 % 20 % 13 % 9 % 0 % 0 % 8 % 19 % 0 % 14 % 0 %
Wales 32 % 0 % 12 % 6 % 60 % 0 % 0 % 20 % 13 % 0 % 10 % 0 % 29 % 0 % 16 % 7 %
France 30 % 0 % 25 % 0 % 18 % 0 % 0 % 0 % 36 % 0 % 0 % 0 % 35 % 0 % 25 % 0 %
All countriesa 49 % 54 % 16 % 5 % 53 % 67 % 19 % 11 % 46 % 41 % 14 % 4 % 49 % 57 % 17 % 5 %
  1. Source: Authors based on information from the websites of the eight HTA agencies; a calculated as the sum of all reimbursed drugs with particular type of recommendation (positive/conditional/negative/no recommendation) from all agencies divided by the sum of all drugs (reimbursed and not reimbursed) with particular type of recommendation from all agencies